Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

Pharmaceutical Technology

JULY 26, 2022

There are two branded miglustat therapies available across the 3MM, with the US market having Johnson and Johnson’s (J&J, US) Zavesca and also generic miglustat available, but neither of these are approved for the treatment of NPC, so physicians prescribe this therapy off-label.

Marketing 122

Marketing Transportation Leads Patients 122

Pharmaceutical Technology

MAY 9, 2023

The 5th Panel of the Federal Court of the 1st Region (Tribunal Regional Federal da 1ª Região, TRF-1) upheld the existing expiry dates of two patents—one for semaglutide itself (2026), and the other for the delivery mechanism for the oral formulation of the drug, Rybelsus (2031). The average patient lost 15.7%

Marketing 59

Marketing Manufacturing Prospecting Physicians 59

Pharmaceutical Technology

AUGUST 12, 2022

This was following a dogged advocacy campaign from ALS clinicians and patients, and the release of additional AMX0035 data. Dr Merit Cudkowicz, a co-principal investigator in Amylyx’s clinical trials, says patients and investigators are pushing for an approval given the unmet need for therapies. “By The FDA’s action plan.

FDA 98

FDA Food and Drug Administration Physicians Side effects 98

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Patients Distribution 52

Clarivate

AUGUST 27, 2024

Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. Abbott’s Volt should join the party in early 2026. Adagio Medical Inc.,

Marketing 52

Marketing Competition FDA Electronics 52

Clarivate

SEPTEMBER 5, 2024

Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. Meanwhile, patients will benefit from a new $2,000 cap on out-of-pocket costs (Read Clarivate’s Primer on the IRA for more details about the law’s reforms).

Insurance 52

Insurance Marketing Manufacturing Prescription 52

PM360

APRIL 7, 2023

Reduced patient out-of-pocket (OOP) costs in Part D have the potential to reduce beneficiary reliance on foundation support, with commensurate reductions in manufacturer donations required. The business-to-business market leaders must find new and creative ways to help patients receive their treatments. The 340B battle will rage on.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Leads Sales 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.

Doctors 59

Doctors Medicine Marketing Sales 59

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. Impact Beyond Medicare The IRA won’t just impact negotiation with the government either. Reference: 1.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

World of DTC Marketing

JULY 28, 2022

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. This would include drugs covered by both Medicare Part B (physician-administered drugs) and Part D (prescription medications).

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

The Inflation Reduction Act instead allows the Centers for Medicare & Medicaid Services to begin negotiating Fair Maximum Prices for a growing list of Part D (outpatient) and Part B (physician-administered) drugs that represent the greatest cost to the federal government. As of Aug.

Healthcare 52

Healthcare Healthcare Government Insurance 52